☆ 4.7 Review

Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management

CARDIOVASCULAR DIABETOLOGY (2022)

Related references

Note: Only part of the references are listed.

Review Cardiac & Cardiovascular Systems

Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association

Joshua J. Joseph et al.

Summary: This scientific statement highlights the importance of controlling cardiovascular risk factors in reducing cardiovascular events in patients with diabetes. It analyzes how newer antihyperglycemic agents, blood pressure control, and lipid-lowering therapies can improve glycemic control and prevent cardiovascular disease in diabetes. Additionally, it emphasizes the significance of lifestyle interventions, pharmacological therapy, and surgical interventions in managing obesity and metabolic syndrome, which are important precursors of diabetes and comorbid cardiovascular disease. Furthermore, it explores the critical role of social determinants of health and health equity in the continuum of care for diabetes and cardiovascular disease.

CIRCULATION (2022)

Add to Collection

Article Endocrinology & Metabolism

6. Glycemic Targets: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association provides clinical practice recommendations and tools for evaluating diabetes care quality through their medical care standards. The standards are updated annually and comments are welcome on their professional website.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

Peter Rossing et al.

Summary: Finerenone improves cardiorenal outcomes in patients with chronic kidney disease and type 2 diabetes, regardless of baseline HbA(1c) levels or insulin use.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association provides clinical practice recommendations and evaluation tools through the Diabetes Standards of Medical Care. The standards are updated annually or more frequently by a multidisciplinary committee.

DIABETES CARE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis

Rajiv Agarwal et al.

Summary: The study found that finerenone can reduce the risk of kidney disease and cardiovascular events in patients with type 2 diabetes. Screening patients for albuminuria can help reduce the burden of cardiovascular and kidney disease.

EUROPEAN HEART JOURNAL (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparison of American and European Guidelines for Primary Prevention of Cardiovascular Disease JACC Guideline Comparison

Isabel Fegers-Wustrow et al.

Summary: This review compares the primary prevention recommendations of the recent 2021 European Society of Cardiology (ESC) and 2019 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines on cardiovascular disease (CVD) prevention. Both guidelines emphasize a holistic approach to prevention and agree on the importance of lifestyle optimization and intensified risk factor management. They differ in their cardiovascular risk assessment tools and acknowledge the role of risk modifiers in refining risk calculation. The ESC guideline recognizes the importance of nonclassical risk factors and calls for legislative action.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study

Peter Rossing et al.

Summary: The study found that Finerenone significantly improved kidney and cardiovascular outcomes in patients with CKD and T2D, and the risks remained consistent regardless of HbA(1c) levels or insulin use.

DIABETES CARE (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

The Safety and Efficacy of Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Systematic Review and Meta-analysis

Yang Hua et al.

Summary: This meta-analysis indicates that rivaroxaban has superior efficacy and safety compared to warfarin in patients with atrial fibrillation and diabetes, with significant reductions in stroke, myocardial infarction, and major adverse cardiac events, as well as lower risks of major bleeding, intracranial hemorrhage, and major gastrointestinal bleeding.

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

Dario Giugliano et al.

Summary: SGLT-2 inhibitors show a reduction in cardiovascular risk and renal efficacy in patients with cardiometabolic and renal diseases, leading to significant reductions in composite CV mortality or hospitalization for heart failure, heart failure, and renal outcomes.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

William T. Abraham et al.

Summary: The two trials showed neutral primary outcomes, but hypothesis-generating improvements were observed in exploratory analyses of secondary endpoints with empagliflozin in HFrEF patients.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Declining mortality in older people with type 2 diabetes masks rising excess risks at younger ages: a population-based study of all-cause and cause-specific mortality over 13 years

Julian W. Sacre et al.

Summary: The study showed that the declining excess mortality attributable to T2DM from 2002-2014 was primarily driven by reductions in those aged 80+ years, with reductions in mortality rates mainly driven by cancer-related deaths in men and cardiovascular disease in women. While declines in total mortality among those with T2DM were observed in more age groups, it was often to a lesser extent than in the general population, thereby increasing the excess risk associated with T2DM.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Endocrinology & Metabolism

GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis

Karan R. Chadda et al.

Summary: GLP-1 agonists show promising efficacy in treating children with obesity and/or T2DM, with positive effects on reducing HbA1c and body weight. Adverse effects mainly include gastrointestinal symptoms and minor hypoglycemic episodes.

OBESITY REVIEWS (2021)

Add to Collection

Article Medicine, General & Internal

Observational study investigating the prevalence of asymptomatic stage B heart failure in patients with type 2 diabetes who are not known to have coronary artery disease

Mon Myat Oo et al.

Summary: The study identified a high prevalence of stage B heart failure in patients with type 2 diabetes without a history of cardiovascular disease in Malaysia. Most participants were female, with a mean body mass index of 27.5 kg/m(2). A large proportion of patients had a history of hypertension and had been living with type 2 diabetes for more than 10 years. Diastolic dysfunction, increased left ventricular mass index, and increased left atrial volume index were common among the study population. Newer anti-diabetes agents were also frequently used in this group.

BMJ OPEN (2021)

Add to Collection

Review Medicine, General & Internal

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Suetonia C. Palmer et al.

Summary: This network meta-analysis evaluated the effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk levels. The study found that both classes of drugs lowered mortality and improved cardiovascular outcomes, with notable differences in effects between the two agents. Additional benefits and adverse effects varied across different risk groups.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism

Trends in Cardiovascular Complications and Mortality among Patients with Diabetes in South Korea

Jung Hwan Park et al.

Summary: From 2006 to 2015, hospitalization rates for major cardiovascular complications decreased in South Korean diabetes patients, while rates for heart failure and peripheral artery disease increased. From 2007 to 2015, mortality rates for cancer, cerebrovascular disease, diabetes, heart disease, and hypertensive disease decreased, but mortality rate for pneumonia increased. Overall, there was a continuous reduction in cardiovascular complications and mortality in adults with diabetes, but efforts are needed to prevent certain diabetes complications.

DIABETES & METABOLISM JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis

Milad Nazarzadeh et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato et al.

Summary: In this study comparing Tirzepatide and glargine in patients with type 2 diabetes inadequately controlled on oral glucose-lowering medications, Tirzepatide demonstrated greater reduction in HbA(1c) and lower incidence of hypoglycemia at week 52, with no excess cardiovascular risk observed compared to glargine.

LANCET (2021)

Add to Collection

Article Endocrinology & Metabolism

Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes

Jae-Seung Yun et al.

Summary: With advancements in diabetes care, incident cardiovascular disease in patients with type 2 diabetes mellitus has decreased. Challenges remain due to CVD being a major cause of death in diabetic patients. Research focuses on reducing cardiovascular risk in T2DM through lifestyle modifications and therapeutic approaches.

METABOLISM-CLINICAL AND EXPERIMENTAL (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials

Houyong Zhu et al.

Summary: A network meta-analysis was conducted to evaluate long-term antithrombotic strategies in chronic coronary syndrome patients with high-risk factors. The results suggest that rivaroxaban plus aspirin is the preferred regimen for reducing cardiovascular events in this patient population.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Article Endocrinology & Metabolism

Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records

Jonathan Pearson-Stuttard et al.

Summary: The study shows a decline in total mortality rates among individuals with diagnosed diabetes between 2001 and 2018, accompanied by a diversification of causes of death, with a significant decrease in vascular disease death rates. Cancers have now become the leading cause of death among individuals with diabetes.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force

Maurizio Averna et al.

Summary: This article from the European Atherosclerosis Society (EAS) provides practical guidance on combination therapy for high-risk and very-high-risk patients with elevated LDL-C and/or TG, emphasizing the use of statin-ezetimibe combination therapy for high LDL-C and considering niacin or high-dose omega-3 fatty acids for patients with elevated TG levels.

ATHEROSCLEROSIS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis

Hang-Long Li et al.

Summary: This study found that SGLT2 inhibitors can reduce the risk of patients developing atrial fibrillation, embolic stroke, atrial fibrillation/flutter, and ventricular tachycardia. The associations were consistent across different baseline conditions and types of SGLT2 inhibitors used.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Naveed Sattar et al.

Summary: The meta-analysis showed that GLP-1 receptor agonists can reduce the risk of major adverse cardiovascular events, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes, regardless of structural homology.

LANCET DIABETES & ENDOCRINOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Novel therapies with precision mechanisms for type 2 diabetes mellitus

Leigh Perreault et al.

Summary: The article discusses the development of new drugs for type 2 diabetes mellitus (T2DM) and emphasizes their mechanisms of action and potential for treating T2DM. The number of clinical trials is increasing, providing more personalized and safe treatment options for T2DM patients.

NATURE REVIEWS ENDOCRINOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Metabolic Dyslipidemia and Cardiovascular Outcomes in Type 2 Diabetes Mellitus: Findings From the Look AHEAD Study

Arnaud D. Kaze et al.

Summary: Metabolic dyslipidemia and low HDL-C are associated with higher risks of cardiovascular disease outcomes in overweight/obese individuals with type 2 diabetes mellitus.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)

Add to Collection

Review Endocrinology & Metabolism

Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review

Esther Artime et al.

Summary: CVD is a major cause of morbidity and mortality in patients with T2DM, with high prevalence rates and increased direct costs associated with care. Early prevention is crucial for improving clinical and economic outcomes.

DIABETES THERAPY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Ofri Mosenzon et al.

Summary: The CAPTURE study aimed to estimate the prevalence of established cardiovascular disease in adults with type 2 diabetes across 13 countries from five continents, and to further characterize the study sample regarding demographics, clinical parameters, and medication usage, particularly focusing on glucose-lowering agents with demonstrated cardiovascular benefits.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)

Frank L. J. Visseren et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial

Scott D. Solomon et al.

Summary: The DELIVER trial is an international, multicenter study that aims to evaluate the efficacy and safety of the SGLT2 inhibitor dapagliflozin in patients with heart failure with preserved and mildly reduced ejection fraction. The primary endpoint is time-to-first cardiovascular death or worsening heart failure event, to be assessed in both the full population and in those with specific ejection fraction criteria. DELIVER will provide insights into the role of dapagliflozin as an adjunct therapy in patients with heart failure.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock et al.

Summary: Tirzepatide demonstrated significant improvements in glycemic control and body weight without increasing the risk of hypoglycemia. The safety profile was consistent with GLP-1 receptor agonists, suggesting a potential monotherapy use for the treatment of type 2 diabetes.

LANCET (2021)

Add to Collection

Review Cell Biology

The aetiology and molecular landscape of insulin resistance

David E. James et al.

Summary: Insulin resistance is an early manifestation of various human diseases, including type 2 diabetes and cardiovascular disease, caused by a combination of genetic and environmental factors. Recent research has highlighted the important role of adipose tissue in the development of insulin resistance by releasing lipids and other factors that disrupt insulin action in other organs. Identifying the targets involved in this unified insulin resistance pathway is crucial for developing new treatments for insulin resistance-related diseases.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frias et al.

Summary: The study showed that Tirzepatide was both noninferior and superior to Semaglutide in terms of the mean change in glycated hemoglobin levels for patients with type 2 diabetes over 40 weeks. Additionally, reductions in body weight were greater with Tirzepatide compared to Semaglutide, with similar rates of gastrointestinal adverse events reported in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Trends in type 2 diabetes mellitus disease burden in European Union countries between 1990 and 2019

Richard Goodall et al.

Summary: The study showed that the prevalence of type 2 diabetes has been increasing in European Union countries over the past 30 years, while mortality rates have generally been decreasing. The UK had the highest relative decrease in mortality rates for males, while Cyprus had the largest relative decrease for females. There are variations in both prevalence and mortality trends across different countries.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Duration of Diabetes and Incident Heart Failure The ARIC (Atherosclerosis Risk In Communities) Study

Justin B. Echouffo-Tcheugui et al.

Summary: This study found that longer duration of diabetes is associated with an increased risk of incident heart failure. The association was stronger among younger individuals, those with poorer glycemic control, higher body mass index, women, and Blacks. The study suggests that delaying diabetes onset may help prevent heart failure, and interventions targeting individuals with long-standing diabetes may improve heart failure outcomes.

JACC-HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Francesco Cosentino et al.

EUROPEAN HEART JOURNAL (2020)

Add to Collection

Article Pharmacology & Pharmacy

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure

Rudolf A. de Boer et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study

Lin Zhu et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Endocrinology & Metabolism

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

John B. Buse et al.

DIABETES CARE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes

Anders Hostrup Larsen et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

Add to Collection

Article Endocrinology & Metabolism

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

David R. Powell et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

Add to Collection

Review Medicine, General & Internal

Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Paul Guedeney et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus A Scientific Statement From the American Heart Association

Suzanne Arnold et al.

CIRCULATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials

Eliano P. Navarese et al.

CIRCULATION (2020)

Add to Collection

Review Medicine, General & Internal

Monotherapy with a P2Y 12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis

Mauro Chiarito et al.

LANCET (2020)

Add to Collection

Review Endocrinology & Metabolism

Young-onset type 2 diabetes mellitus - implications for morbidity and mortality

Dianna J. Magliano et al.

NATURE REVIEWS ENDOCRINOLOGY (2020)

Add to Collection

Article Endocrinology & Metabolism

Metformin use in prediabetes: is earlier intervention better?

Andrew Warrilow et al.

ACTA DIABETOLOGICA (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents A Systematic Review and Network Meta-Analysis

Safi U. Khan et al.

CIRCULATION (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12Inhibitor in Patients After Percutaneous Coronary Intervention A Systematic Review and Meta-Analysis

Michelle L. O'Donoghue et al.

CIRCULATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

Naoto Katakami et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials

Wen-jie Li et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

Francesco Cosentino et al.

CIRCULATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome Still Sacrosanct or Is Reappraisal Warranted?

Alan P. Jacobsen et al.

CIRCULATION (2020)

Add to Collection

Article Medicine, General & Internal

Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis

Xiaoyan Cai et al.

BMJ-British Medical Journal (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Endocrinology & Metabolism

Discontinuing Aspirin After Short Term Use Versus Continuous Use with a P2Y12 Inhibitor for the Treatment of Patients with Type 2 Diabetes Mellitus Following Percutaneous Coronary Intervention: A Meta-analysis

Qiang Wang et al.

DIABETES THERAPY (2020)

Add to Collection

Article Endocrinology & Metabolism

Magnitude of, and Factors Associated with Cardiovascular Disease Among Type Two Diabetes Mellitus Patients

Adane Tesfaye et al.

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)

Add to Collection

Review Endocrinology & Metabolism

Global trends in diabetes complications: a review of current evidence

Jessica L. Harding et al.

DIABETOLOGIA (2019)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program

Gemma A. Figtree et al.

CIRCULATION (2019)

Add to Collection

Review Endocrinology & Metabolism

Standards of medical care for type 2 diabetes in China 2019

Weiping Jia et al.

DIABETES-METABOLISM RESEARCH AND REVIEWS (2019)

Add to Collection

Article Endocrinology & Metabolism

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Natasha C. Bergmann et al.

DIABETOLOGIA (2019)

Add to Collection

Review Medicine, General & Internal

Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events A Systematic Review and Meta-analysis

Sean L. Zheng et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Review Endocrinology & Metabolism

Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management

Stephanie A. Amiel et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies

Xiaofeng Ye et al.

CARDIOVASCULAR DIABETOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial

Mohapradeep Mohan et al.

EUROPEAN HEART JOURNAL (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update

Shannon M. Dunlay et al.

CIRCULATION (2019)

Add to Collection

Review Medicine, General & Internal

Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis

Shang-He-Lin Yin et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD New features and the 'Ten Commandments' of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen

Peter J. Grant et al.

EUROPEAN HEART JOURNAL (2019)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis

Lorenzo M. Vetrone et al.

ACTA DIABETOLOGICA (2019)

Add to Collection

Review Cardiac & Cardiovascular Systems

Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants

Yang Hu et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)

Add to Collection

Review Endocrinology & Metabolism

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Soren L. Kristensen et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials

Ahmed N. Mahmoud et al.

EUROPEAN HEART JOURNAL (2019)

Add to Collection

Review Medicine, General & Internal

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Thomas A. Zelniker et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials

Konstantinos C. Koskinas et al.

EUROPEAN HEART JOURNAL (2018)

Add to Collection

Review Cardiac & Cardiovascular Systems

Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017

Thomas R. Einarson et al.

CARDIOVASCULAR DIABETOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study

Mikhail Kosiborod et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data

Edward W. Gregg et al.

LANCET (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes

Safi U. Khan et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Platelet activity and hypercoagulation in type 2 diabetes

Lesha Pretorius et al.

CARDIOVASCULAR DIABETOLOGY (2018)

Add to Collection

Article Endocrinology & Metabolism

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies et al.

DIABETES CARE (2018)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Juan Pablo Frias et al.

LANCET (2018)

Add to Collection

Review Endocrinology & Metabolism

Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease

Guanghong Jia et al.

DIABETOLOGIA (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus 10-Year Follow-Up of a Randomized Controlled Trial

Yoshihiko Saito et al.

CIRCULATION (2017)

Add to Collection

Article Medicine, General & Internal

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

Aidin Rawshani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Endocrinology & Metabolism

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial

Olga Vaccaro et al.

LANCET DIABETES & ENDOCRINOLOGY (2017)

Add to Collection

Article Cell Biology

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Juan Pablo Frias et al.

CELL METABOLISM (2017)

Add to Collection

Article Endocrinology & Metabolism

Declining Trends of Cardiovascular-Renal Complications and Mortality in Type 2 Diabetes: The Hong Kong Diabetes Database

Andrea O. Y. Luk et al.

DIABETES CARE (2017)

Add to Collection

Article Endocrinology & Metabolism

Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes

M. A. Bethel et al.

DIABETIC MEDICINE (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study

Douglas H. J. Elder et al.

EUROPEAN JOURNAL OF HEART FAILURE (2016)

Add to Collection

Article Oncology

Phase II study of metformin for reduction of obesity-associated breast cancer risk: a randomized controlled trial protocol

Jessica A. Martinez et al.

BMC CANCER (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study

Francesco Franchi et al.

CIRCULATION (2016)

Add to Collection

Article Endocrinology & Metabolism

Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis

Edoardo Mannucci et al.

DIABETES CARE (2016)

Add to Collection

Article Medicine, General & Internal

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

W. N. Kernan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Oncology

Diverse roles of miR-335 in development and progression of cancers

Long-ji Luo et al.

TUMOR BIOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis

Yuli Huang et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

Add to Collection

Article Medicine, General & Internal

Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis

Yuli Huang et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial

Pardeep S. Jhund et al.

EUROPEAN HEART JOURNAL (2015)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Endocrinology & Metabolism

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy

Julio Rosenstock et al.

DIABETES CARE (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberte Paclitaxel-Eluting Coronary Stent Placement

Kirk N. Garratt et al.

CIRCULATION (2015)

Add to Collection

Article Endocrinology & Metabolism

Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease

Jie Hong et al.

DIABETES CARE (2013)

Add to Collection

Article Medicine, General & Internal

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Endocrinology & Metabolism

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

S. E. Inzucchi et al.

DIABETOLOGIA (2012)

Add to Collection

Article Peripheral Vascular Disease

Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome

Katie Ayers et al.

HYPERTENSION (2012)

Add to Collection

Article Medicine, General & Internal

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia

Hertzel C. Gerstein et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Hematology

Thrombus and antiplatelet therapy in type 2 diabetes mellitus A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina

Girish N. Viswanathan et al.

THROMBOSIS AND HAEMOSTASIS (2012)

Add to Collection

Article Medicine, General & Internal

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

N. Sarwar et al.

LANCET (2010)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

C. Baigent et al.

LANCET (2010)

Add to Collection

Article Cardiac & Cardiovascular Systems

Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)

Arijit Dasgupta et al.

AMERICAN JOURNAL OF CARDIOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Aspirin Use and Risk of Type 2 Diabetes in Apparently Healthy Men

Yasuaki Hayashino et al.

AMERICAN JOURNAL OF MEDICINE (2009)

Add to Collection

Article Medicine, General & Internal

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

LANCET (2009)

Add to Collection

Article Medicine, General & Internal

10-year follow-up of intensive glucose control in type 2 diabetes

Rury R. Holman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Cardiac & Cardiovascular Systems

Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study

Dominick J. Angiolillo et al.

CIRCULATION (2007)

Add to Collection

Article Endocrinology & Metabolism

The Prospective Pioglitazone Clinical Trial in Macrovascuar Events (PROactive) - Can ploglitazone reduce cardiovascular events in diabetes? - Study design and baseline characteristics of 5,238 patients

B Charbonnel et al.

DIABETES CARE (2004)

Add to Collection

Article Endocrinology & Metabolism

Insulin resistance and cardiovascular events with low HDL cholesterol - The Veterans Affairs HDL Intervention Trial (VA-HIT)

SJ Robins et al.

DIABETES CARE (2003)

Add to Collection

Article Medicine, General & Internal

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

IM Stratton et al.

BMJ-BRITISH MEDICAL JOURNAL (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.